Allogene TherapeuticsALLO
About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Employees: 361
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
23% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 48
18% more capital invested
Capital invested by funds: $400M [Q2] → $472M (+$72.2M) [Q3]
1.58% less ownership
Funds ownership: 82.15% [Q2] → 80.57% (-1.58%) [Q3]
10% less funds holding
Funds holding: 172 [Q2] → 154 (-18) [Q3]
11% less call options, than puts
Call options by funds: $354K | Put options by funds: $399K
59% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 27
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Piper Sandler Biren Amin 10% 1-year accuracy 2 / 20 met price target | 369%upside $9 | Overweight Maintained | 14 Nov 2024 |
HC Wainwright & Co. Robert Burns 28% 1-year accuracy 45 / 162 met price target | 369%upside $9 | Buy Reiterated | 8 Nov 2024 |
Financial journalist opinion
Based on 4 articles about ALLO published over the past 30 days
